Kate Roberts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kate Roberts has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ayesha Appa
University of California Division of HIV, ID and Global Medicine, Department of Medicine San Francisco, San Francisco, California
3 shared publications - Gabriel Chamie
Department of Medicine University of California San Francisco California USA
3 shared publications - Lauren Suchman
University of California, San Francisco, San Francisco, CA, United States
3 shared publications - Monica Gandhi
Division of HIV, Infectious Disease, and Global Medicine, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA
3 shared publications - Phillip Oliver Coffin
San Francisco Department of Public Health, Center on Substance Use and Health
3 shared publications - Elise D. Riley
Department of Medicine, University of California, San Francisco, San Francisco, USA
2 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e728-e734
Integrating HIV and Stimulant Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
Background: Stimulants, including cocaine and methamphetamine, are associated with HIV transmission and viremia. Contingency management (CM), which provides financial incentives for non-reactive urine testing, is first-line treatment for stimulant use disorder (StUD), yet has been minimally studied or integrated into HIV care. Methods: We conducted a 12-week, single-arm implementation-effectiveness pilot of weekly CM in a safety-net HIV clinic for living with HIV (PWH) who have StUD. Participants received escalating incentives for stimulant-negative and/or tenofovir-reactive point-of-care urine assays. Using the RE-AIM framework, we evaluated Reach (demographics, attendance), Effectiveness (stimulant-negative/tenofovir-positive tests, HIV virologic suppression [VS]), and Implementation. We conducted semi-structured, in-depth participant interviews following intervention completion to explore perceived impact and implementation. Results: From September 2023 to February 2024, we enrolled 31 PWH with StUD: 77% used methamphetamine, 35% cocaine, and 19% fentanyl. Only 17/31 (55%) had VS at baseline. Participants attended a mean of 5/12 visits (42%). Among PWH who attended post-enrollment visits (26/31), 61/110 (56%) stimulant tests were negative and 98% (89/91) of tenofovir tests were positive. Post-intervention, 88% (23/26) of retained participants achieved VS (p<0.01). Qualitative interviews revealed factors enhancing Reach (embedding CM within HIV care), Effectiveness (incentives supporting adherence self-efficacy; program providing structure and motivation), and Implementation (supportive staff relationships, non-judgmental approach). Conclusions: Contingency management for stimulant use and/or ART adherence (using point-of-care tenofovir assays) embedded into HIV care was associated with reduced stimulant use and gains in viral suppression. Scalability of integrating HIV and stimulant use disorder management using CM merits further evaluation.
- 8 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e728-e734
Open AccessIntegrating HIV and Stimulant Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
Background: Stimulants, including cocaine and methamphetamine, are associated with HIV transmission and viremia. Contingency management (CM), which provides financial incentives for non-reactive urine testing, is first-line treatment for stimulant use disorder (StUD), yet has been minimally studied or integrated into HIV care. Methods: We conducted a 12-week, single-arm implementation-effectiveness pilot of weekly CM in a safety-net HIV clinic for living with HIV (PWH) who have StUD. Participants received escalating incentives for stimulant-negative and/or tenofovir-reactive point-of-care urine assays. Using the RE-AIM framework, we evaluated Reach (demographics, attendance), Effectiveness (stimulant-negative/tenofovir-positive tests, HIV virologic suppression [VS]), and Implementation. We conducted semi-structured, in-depth participant interviews following intervention completion to explore perceived impact and implementation. Results: From September 2023 to February 2024, we enrolled 31 PWH with StUD: 77% used methamphetamine, 35% cocaine, and 19% fentanyl. Only 17/31 (55%) had VS at baseline. Participants attended a mean of 5/12 visits (42%). Among PWH who attended post-enrollment visits (26/31), 61/110 (56%) stimulant tests were negative and 98% (89/91) of tenofovir tests were positive. Post-intervention, 88% (23/26) of retained participants achieved VS (p<0.01). Qualitative interviews revealed factors enhancing Reach (embedding CM within HIV care), Effectiveness (incentives supporting adherence self-efficacy; program providing structure and motivation), and Implementation (supportive staff relationships, non-judgmental approach). Conclusions: Contingency management for stimulant use and/or ART adherence (using point-of-care tenofovir assays) embedded into HIV care was associated with reduced stimulant use and gains in viral suppression. Scalability of integrating HIV and stimulant use disorder management using CM merits further evaluation.
- Open Access
- 18 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e67292
Harm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study
Background: Stimulant use disorder has been linked with medication nonadherence and mortality among people living with HIV. Contingency management (CM) is a strategy incentivizing measurable behavior change that is recommended as the first-line treatment for stimulant use disorder and can support antiretroviral therapy (ART) adherence. However, CM is not widely implemented, in part due to feasibility concerns. Although reductions in substance use short of full abstinence can improve health outcomes, CM programs typically target complete abstinence from stimulant use rather than reduction. To optimize care for safety-net populations living with comorbid stimulant use disorder and HIV, we designed a novel CM program incentivizing both stimulant use reduction and ART adherence in the HIV ambulatory setting. Objective: We aimed to (1) evaluate the feasibility of once-weekly CM in safety-net HIV ambulatory care and (2) assess the acceptability of CM among participants and care providers. Methods: We will conduct a pilot, single-arm, hybrid implementation effectiveness trial offering a novel CM intervention in 2 low-barrier, ambulatory HIV clinics. Patients with stimulant use disorder and suboptimal ART adherence will be offered 12 weeks of once-weekly CM including incentives for positive-tenofovir and negative-stimulant results on urine point-of-care assays. We will assess stimulant use once weekly using tests with a 4-day detection window, allowing participants to use stimulants during select days of the week but earn incentives by reducing their frequency of use from near-daily use. We will assess feasibility and acceptability using quantitative process methods and qualitative in-depth interviews, guided by the RE-AIM (reach, effectiveness, acceptability, implementation, and maintenance) evaluation framework. We will define preliminary effectiveness by proportion of stimulant-negative and tenofovir-positive urine tests, as well as changes in HIV viral suppression before and after participation. Results: Recruitment and CM visits have concluded as of September 2024. Quantitative and qualitative evaluation is underway and is expected to continue through October 2025. Conclusions: This novel CM program offers dual incentives targeting stimulant use reduction and ART adherence. We hypothesize that incentivizing stimulant use reduction is acceptable to our target safety-net population. Demonstration of a feasible, acceptable model may serve as a first step toward wider use of stimulant-reduction CM in the safety-net setting. Trial Registration: ClinicalTrials.gov NCT06564792; https://clinicaltrials.gov/study/NCT06564792 International Registered Report Identifier (IRRID): DERR1-10.2196/67292
- 18 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e67292
Open AccessHarm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study
Background: Stimulant use disorder has been linked with medication nonadherence and mortality among people living with HIV. Contingency management (CM) is a strategy incentivizing measurable behavior change that is recommended as the first-line treatment for stimulant use disorder and can support antiretroviral therapy (ART) adherence. However, CM is not widely implemented, in part due to feasibility concerns. Although reductions in substance use short of full abstinence can improve health outcomes, CM programs typically target complete abstinence from stimulant use rather than reduction. To optimize care for safety-net populations living with comorbid stimulant use disorder and HIV, we designed a novel CM program incentivizing both stimulant use reduction and ART adherence in the HIV ambulatory setting. Objective: We aimed to (1) evaluate the feasibility of once-weekly CM in safety-net HIV ambulatory care and (2) assess the acceptability of CM among participants and care providers. Methods: We will conduct a pilot, single-arm, hybrid implementation effectiveness trial offering a novel CM intervention in 2 low-barrier, ambulatory HIV clinics. Patients with stimulant use disorder and suboptimal ART adherence will be offered 12 weeks of once-weekly CM including incentives for positive-tenofovir and negative-stimulant results on urine point-of-care assays. We will assess stimulant use once weekly using tests with a 4-day detection window, allowing participants to use stimulants during select days of the week but earn incentives by reducing their frequency of use from near-daily use. We will assess feasibility and acceptability using quantitative process methods and qualitative in-depth interviews, guided by the RE-AIM (reach, effectiveness, acceptability, implementation, and maintenance) evaluation framework. We will define preliminary effectiveness by proportion of stimulant-negative and tenofovir-positive urine tests, as well as changes in HIV viral suppression before and after participation. Results: Recruitment and CM visits have concluded as of September 2024. Quantitative and qualitative evaluation is underway and is expected to continue through October 2025. Conclusions: This novel CM program offers dual incentives targeting stimulant use reduction and ART adherence. We hypothesize that incentivizing stimulant use reduction is acceptable to our target safety-net population. Demonstration of a feasible, acceptable model may serve as a first step toward wider use of stimulant-reduction CM in the safety-net setting. Trial Registration: ClinicalTrials.gov NCT06564792; https://clinicaltrials.gov/study/NCT06564792 International Registered Report Identifier (IRRID): DERR1-10.2196/67292
- 22 July 2025
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (1) , 49-56
“It Eats My Heart”: Identifying Knowledge Gaps in Injection Drug-Related Endocarditis Among Hospitalized Patients
Background: Infective endocarditis (IE) rates have risen sharply, spurred by injection drug use (IDU). Public health interventions to prevent infectious complications of IDU have primarily focused on communicable diseases, such as HIV and viral hepatitis. We assessed patients’ knowledge of IE in relation to IDU practice. Methods: From 2021 to 2022, we conducted in-person semi-structured interviews (SSIs) with 16 adults hospitalized with IDU-related IE at an academic medical center in North Carolina. SSIs explored participants’ knowledge and experience of IE and IDU practices. The SSIs were audio-recorded, transcribed verbatim, and thematically coded. Results: We identified 4 primary themes: limited knowledge of IE; nonspecific IE symptoms; injection behavior and infection prevention; and knowledge of other IDU-related infections, such as hepatitis C virus (HCV) and HIV. Most patients reported little or no knowledge of IE before hospitalization despite previously having soft tissue infections, such as skin abscesses. Presentations were heterogeneous, with many patients not recognizing their symptoms as IE, and often delaying seeking care. In contrast to limited information about IE, all patients reported prior testing for HIV and HCV. While many expressed the importance of not reusing injection equipment, many patients reported reusing injection equipment nonetheless, and several specifically reported that they take no dedicated precautions to prevent infections. Conclusion: Our findings suggest prior to hospitalizations, knowledge of IE, its symptoms, and prevention is limited among persons who inject drugs who acquire IE. Our study indicates an urgent need to disseminate public health messages regarding preventing IDU-related invasive bacterial infections and providing access to sterile equipment to prevent bacterial infections.
- 22 July 2025
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (1) , 49-56
“It Eats My Heart”: Identifying Knowledge Gaps in Injection Drug-Related Endocarditis Among Hospitalized Patients
Background: Infective endocarditis (IE) rates have risen sharply, spurred by injection drug use (IDU). Public health interventions to prevent infectious complications of IDU have primarily focused on communicable diseases, such as HIV and viral hepatitis. We assessed patients’ knowledge of IE in relation to IDU practice. Methods: From 2021 to 2022, we conducted in-person semi-structured interviews (SSIs) with 16 adults hospitalized with IDU-related IE at an academic medical center in North Carolina. SSIs explored participants’ knowledge and experience of IE and IDU practices. The SSIs were audio-recorded, transcribed verbatim, and thematically coded. Results: We identified 4 primary themes: limited knowledge of IE; nonspecific IE symptoms; injection behavior and infection prevention; and knowledge of other IDU-related infections, such as hepatitis C virus (HCV) and HIV. Most patients reported little or no knowledge of IE before hospitalization despite previously having soft tissue infections, such as skin abscesses. Presentations were heterogeneous, with many patients not recognizing their symptoms as IE, and often delaying seeking care. In contrast to limited information about IE, all patients reported prior testing for HIV and HCV. While many expressed the importance of not reusing injection equipment, many patients reported reusing injection equipment nonetheless, and several specifically reported that they take no dedicated precautions to prevent infections. Conclusion: Our findings suggest prior to hospitalizations, knowledge of IE, its symptoms, and prevention is limited among persons who inject drugs who acquire IE. Our study indicates an urgent need to disseminate public health messages regarding preventing IDU-related invasive bacterial infections and providing access to sterile equipment to prevent bacterial infections.
- Open Access
- 8 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Harm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study (Preprint)
BACKGROUND Stimulant use disorder has been linked with medication nonadherence and mortality among people living with HIV. Contingency management (CM) is a strategy incentivizing measurable behavior change that is recommended as the first-line treatment for stimulant use disorder and can support antiretroviral therapy (ART) adherence. However, CM is not widely implemented, in part due to feasibility concerns. Although reductions in substance use short of full abstinence can improve health outcomes, CM programs typically target complete abstinence from stimulant use rather than reduction. To optimize care for safety-net populations living with comorbid stimulant use disorder and HIV, we designed a novel CM program incentivizing both stimulant use reduction and ART adherence in the HIV ambulatory setting. OBJECTIVE We aimed to (1) evaluate the feasibility of once-weekly CM in safety-net HIV ambulatory care and (2) assess the acceptability of CM among participants and care providers. METHODS We will conduct a pilot, single-arm, hybrid implementation effectiveness trial offering a novel CM intervention in 2 low-barrier, ambulatory HIV clinics. Patients with stimulant use disorder and suboptimal ART adherence will be offered 12 weeks of once-weekly CM including incentives for positive-tenofovir and negative-stimulant results on urine point-of-care assays. We will assess stimulant use once weekly using tests with a 4-day detection window, allowing participants to use stimulants during select days of the week but earn incentives by reducing their frequency of use from near-daily use. We will assess feasibility and acceptability using quantitative process methods and qualitative in-depth interviews, guided by the RE-AIM (reach, effectiveness, acceptability, implementation, and maintenance) evaluation framework. We will define preliminary effectiveness by proportion of stimulant-negative and tenofovir-positive urine tests, as well as changes in HIV viral suppression before and after participation. RESULTS Recruitment and CM visits have concluded as of September 2024. Quantitative and qualitative evaluation is underway and is expected to continue through October 2025. CONCLUSIONS This novel CM program offers dual incentives targeting stimulant use reduction and ART adherence. We hypothesize that incentivizing stimulant use reduction is acceptable to our target safety-net population. Demonstration of a feasible, acceptable model may serve as a first step toward wider use of stimulant-reduction CM in the safety-net setting. CLINICALTRIAL ClinicalTrials.gov NCT06564792; https://clinicaltrials.gov/study/NCT06564792 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/67292
- 8 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHarm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study (Preprint)
BACKGROUND Stimulant use disorder has been linked with medication nonadherence and mortality among people living with HIV. Contingency management (CM) is a strategy incentivizing measurable behavior change that is recommended as the first-line treatment for stimulant use disorder and can support antiretroviral therapy (ART) adherence. However, CM is not widely implemented, in part due to feasibility concerns. Although reductions in substance use short of full abstinence can improve health outcomes, CM programs typically target complete abstinence from stimulant use rather than reduction. To optimize care for safety-net populations living with comorbid stimulant use disorder and HIV, we designed a novel CM program incentivizing both stimulant use reduction and ART adherence in the HIV ambulatory setting. OBJECTIVE We aimed to (1) evaluate the feasibility of once-weekly CM in safety-net HIV ambulatory care and (2) assess the acceptability of CM among participants and care providers. METHODS We will conduct a pilot, single-arm, hybrid implementation effectiveness trial offering a novel CM intervention in 2 low-barrier, ambulatory HIV clinics. Patients with stimulant use disorder and suboptimal ART adherence will be offered 12 weeks of once-weekly CM including incentives for positive-tenofovir and negative-stimulant results on urine point-of-care assays. We will assess stimulant use once weekly using tests with a 4-day detection window, allowing participants to use stimulants during select days of the week but earn incentives by reducing their frequency of use from near-daily use. We will assess feasibility and acceptability using quantitative process methods and qualitative in-depth interviews, guided by the RE-AIM (reach, effectiveness, acceptability, implementation, and maintenance) evaluation framework. We will define preliminary effectiveness by proportion of stimulant-negative and tenofovir-positive urine tests, as well as changes in HIV viral suppression before and after participation. RESULTS Recruitment and CM visits have concluded as of September 2024. Quantitative and qualitative evaluation is underway and is expected to continue through October 2025. CONCLUSIONS This novel CM program offers dual incentives targeting stimulant use reduction and ART adherence. We hypothesize that incentivizing stimulant use reduction is acceptable to our target safety-net population. Demonstration of a feasible, acceptable model may serve as a first step toward wider use of stimulant-reduction CM in the safety-net setting. CLINICALTRIAL ClinicalTrials.gov NCT06564792; https://clinicaltrials.gov/study/NCT06564792 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/67292